Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › bupropion

bupropion

4 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of bupropion

56 trials tracked of bupropion: 34 in phase 3 or 4 and 11 with published results. The most-cited published study has 149 citations.

56Trials tracked
34Phase 3 & 4
0Recruiting
11With published results
Phase distribution
Phase 4 19 Phase 3 15 Phase 2 14 Phase 1 5 Other / NA 3
  1. Phase 4 Study To Evaluate Cardiac Assessments Following Different Treatments Of Smoking Cessation Medications In Subjects With And Without Psychiatric Disorders. Completed · 149 cited
  2. Phase 3 Pharmacogenetics, Emotional Reactivity and Smoking Completed · 134 cited
  3. Phase 4 Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking Completed · 112 cited
  4. Phase 3 Combining Varenicline and Bupropion for Smoking Cessation Completed · 112 cited
  5. Phase 3 Effectiveness of Bupropion for Smokers Recovering From Alcohol Dependence Completed · 95 cited
  6. Phase 3 Disease Management for Smoking Cessation Completed · 77 cited
Show 44 more trials
  1. Phase 4 Naltrexone and Bupropion Combination on Obese,Smoking Patients With Schizophrenia Completed · 27 cited
  2. Phase 4 Study Evaluating The Safety And Efficacy Of Varenicline and Bupropion For Smoking Cessation In Subjects With And Without A History Of Psychiatric Disorders Completed · 25 cited
  3. Phase 4 Extended Treatment for Smoking Cessation Completed · 23 cited
  4. Phase 3 CPT and Smoking Cessation Completed · 10 cited
  5. Phase 3 Individualizing Pharmacotherapy for African American Smokers Completed · 10 cited
  6. Phase 4 STOP Study: Effectiveness of Zyban in a Clinical Population Completed
  7. Phase 4 CYP2B6 Genetics and Drug Interactions in Healthy Volunteers Completed
  8. Phase 4 Dichotic Listening as a Predictor of Medication Response in Depression Completed
  9. Phase 4 Abstinence Reinforcement Therapy (ART) for Homeless Veteran Smokers Completed
  10. Phase 4 Investigation of Genetic Predictors of the Response to Selective Serotonin Re-uptake Inhibitors (SSRI) Treatment Completed
  11. Phase 4 Mobile Health Technology to Enhance Abstinence in Smokers With Schizophrenia Completed
  12. Phase 4 Bupropion for ADHD in Adolescents With Substance Use Disorder Completed
  13. Phase 4 Effect of Antidepressants on Sex Hormone Levels and Sexual Functioning Completed
  14. Phase 4 Mobile Contingency Management for Concurrent Abstinence From Alcohol and Smoking Completed
  15. Phase 4 Mobile Evidence-Based Smoking Cessation for Veterans Living With HIV (MESH) Completed
  16. Phase 4 Bupropion and Weight Control for Smoking Cessation - 1 Completed
  17. Phase 4 Smoking Cessation Medications: Efficacy, Mechanisms and Algorithms Completed
  18. Phase 4 Distribution of Bupropion and Varenicline to Increase Smoking Cessation Attempts Completed
  19. Phase 4 Smoking Cessation Intervention: Effectiveness in Primary Care Completed
  20. Phase 3 Mechanistic Evaluations of Pre-Cessation Therapies for Smoking Cessation Completed
  21. Phase 3 Study to Evaluate the Efficacy, Safety and Tolerability of Bupropion Hydrochloride Extended-release Tablet, and Escitalopram Oxalate Capsule in Subjects With Major Depressive Disorder Completed
  22. Phase 3 Human Laboratory Study of Varenicline and Bupropion for Nicotine Dependence Completed
  23. Phase 3 Zonisamide/Bupropion Effects on Switching to Electronic Cigarettes Completed
  24. Phase 3 Addressing Dementia Via Agitation-Centered Evaluation Completed
  25. Phase 3 Smoking Cessation Interventions for People Living With HIV in Nairobi, Kenya Completed
  26. Phase 3 Craving, Binge Eating and Obesity Completed
  27. Phase 3 Concurrent Bupropion / Varenicline for Smoking Cessation Completed
  28. Phase 3 Bupropion and Restless Legs Syndrome Completed
  29. Phase 2 Contingent Incentives Plus Bupropion for Smoking in People With Schizophrenia Completed
  30. Phase 2 Bupropion in Helping Adults Stop Smoking Completed
  31. Phase 2 Comparing Smoking Treatment Programs for Lighter Smokers - 1 Completed
  32. Phase 2 Study Of 323U66 SR In Major Depressive Disorder Completed
  33. Phase 2 The Effect of Varenicline (Chantix) and Bupropion (Zyban) on Smoking Lapse Behavior Completed
  34. Phase 2 Assessing Symptomatic Clinical Episodes in Depression Completed
  35. Phase 2 Varenicline and Smoking Cessation in Schizophrenia Completed
  36. Phase 2 An Open Label Trial of Bupropion and Naltrexone for Binge Drinking Completed
  37. Phase 2 Low-Dose Naltrexone Combined With Bupropion to Stop Smoking With Less Weight Gain Completed
  38. Phase 2 Study of Medical Treatment for Methamphetamine Addiction Completed
  39. Phase 2 Buproprion for Binge Drinking Completed
  40. Phase 2 Phase 2, Double-Blind, Placebo-Controlled Trial of Bupropion for Methamphetamine Dependence Completed
  41. Phase 2 Placebo-controlled Trial of Bupropion for Smoking Cessation in Pregnant Women Completed
  42. Phase 2 Acceptability of Pharmacologic Treatment for Methamphetamine Dependence Among MSM Completed
  43. Phase 1 A Study in Healthy Men and Women to Test Whether BI 1569912 Influences the Amount of Repaglinide, Midazolam and Bupropion in the Blood Completed
  44. Phase 1 Study of ALXN1840 on the Metabolism of a CYP2B6 Substrate in Healthy Participants Completed

Showing the 50 most-cited and recently-updated of 56 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
FDA Approves Auvelity (dextromethorphan/bupropion) for Major Depressive Disorder and Agitation in Alzheimer's
Psychiatry FDA Approval
FDA Approves Auvelity (dextromethorphan/bupropion) for Major Depressive Disorder and Agitation in Alzheimer's FDA approves new drug Auvelity for depression and Alzheimer's agitation.
The FDA approved Auvelity (dextromethorphan/bupropion) for major depressive disorder (MDD) and agitation associated with dementia due to Alz…
The FDA approved Auvelity for major depressive disorder and agitation in Alzheimer's disease. It combines two medicines into one pill. This …
FDA May 5, 2026
Naltrexone-Bupropion Aids Weight Loss in Overweight Adults With Depression
Diabetes & Endocrinology RCT
Naltrexone-Bupropion Aids Weight Loss in Overweight Adults With Depression A New Weight Loss Drug Helps Depression Too
A pooled analysis of 4 double-blind trials found that naltrexone-bupropion (NB-ER) led to significantly greater weight loss than placebo in …
A new weight loss drug helps people lose more weight while keeping their mood stable and safe for those with mild depression.
May 1, 2026
Adding Bupropion or Varenicline to NRT After ACS Linked to Lower Mortality
Cardiology Cohort
Adding Bupropion or Varenicline to NRT After ACS Linked to Lower Mortality Adding Prescription Meds to Nicotine Patches Lowers Heart Death Risk
This retrospective cohort study of 8,574 propensity-matched pairs found that adding bupropion or varenicline to NRT after ACS was associated…
Heart attack survivors who quit smoking with extra prescription help live longer.
medRxiv Apr 24, 2026
FDA Approves Bupropion Hydrochloride Extended-Release Tablets (SR) (bupropion) for Major Depressive Disorder
Psychiatry FDA Approval
FDA Approves Bupropion Hydrochloride Extended-Release Tablets (SR) (bupropion) for Major Depressive Disorder FDA approves a new, longer-acting version of the antidepressant bupropion
The FDA has approved Bupropion Hydrochloride Extended-Release Tablets (SR) for the treatment of major depressive disorder (MDD).
A new extended-release antidepressant now helps adults manage depression for up to 44 weeks following initial treatment.
FDA Apr 2, 2026